Q2
CLLS — Q2 2026 Financial Report Analysis
Cellectis's Q2 net loss narrowed to $21.8M only because of currency and warrant gains; AstraZeneca revenue fell 69% and the operating loss more than doubled, leaving $169M of cash and a runway into Q4 2027 ahead of a Q4 2026 pivotal-trial readout.